Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-04991532, a Hepatoselective Glucokinase Activator (GKA), Administered as Monotherapy in Japanese and Non-Japanese T2DM Patients

被引：0
|
作者：
Kazierad, David
Bergman, Arthur
Pfefferkorn, Jeffrey A.
Wang, Xin
Rolph, Timothy
Rusnak, James M.
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1108-P
引用
收藏
页码：A287 / A288
页数：2
相关论文
共 25 条
  • [1] Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-04991532, a Hepatoselective Glucokinase Activator (GKA), in T2DM Patients on Metformin Therapy
    Gustavson, Stephanie M.
    Pfefferkorn, Jeffrey A.
    Kazierad, David J.
    Chen, Danny
    Bergman, Arthur
    Wang, Xin
    Rolph, Timothy
    Rusnak, James M.
    DIABETES, 2013, 62 : A671 - A671
  • [2] The Hepatoselective Glucokinase Activator (GKA) PF-04991532, Lowers HbA1c after 12-Weeks of Dosing in Patients With Type 2 Diabetes (T2DM)
    Kazierad, David J.
    Pfefferkorn, Jeffrey A.
    Bergman, Arthur
    Wang, Xin
    Rolph, Timothy P.
    Rusnak, James M.
    DIABETES, 2013, 62 : A271 - A271
  • [3] Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-06291874 (PF), a Glucagon Receptor Antagonist, in Subjects with T2DM
    Kazierad, David J.
    Bergman, Arthur
    Tan, Beesan
    Somayaji, Veena
    Lee, Douglas S.
    Rolph, Timothy
    DIABETES, 2015, 64 : A310 - A311
  • [4] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
    Tamborlane, William
    Polidori, David
    Di Prospero, Nicolas
    DIABETES, 2017, 66 : A371 - A371
  • [5] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin (DAPA) in Combination with Insulin in Japanese Patients with T1D
    Watada, Hirotaka
    Shiramoto, Masanari
    Ueda, Shinya
    Tang, Weifeng
    Asano, Michiko
    Thoren, Fredrik A.
    Kim, Hyosung
    Yajima, Toshitaka
    Boulton, David W.
    Araki, Eiichi
    DIABETES, 2018, 67
  • [6] LY2599506, a Novel Glucokinase Activator (GKA), Improves Fasting and Postprandial Glucose in Patients with Type 2 Diabetes Mellitus (T2DM)
    Bue-Valleskey, Juliana M.
    Schneck, Karen B.
    Sinha, Vikram P.
    Wondmagegnehu, Eshetu T.
    Kapitza, Christoph
    Miller, Jeffrey W.
    DIABETES, 2011, 60 : A272 - A272
  • [7] Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: A comparison between Japanese and non-Japanese patients
    Haba, T
    Uchida, K
    Katayama, A
    Tominaga, Y
    Sato, T
    Watanabe, I
    Inagaki, H
    Kimata, T
    Goto, K
    Morozumi, K
    Takeda, A
    Takahara, S
    Takahashi, K
    Oshima, S
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3174 - 3175
  • [8] Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist HRS9531 in T2DM patients
    Zhao, L.
    Wen, Q.
    Zhang, Y.
    Yu, G.
    Pan, T.
    Wang, Y.
    Li, F.
    Jin, P.
    Jiang, H.
    Zeng, M.
    Li, X.
    Li, X.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [9] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)
    Kadowaki, Takashi
    Haneda, Masakazu
    Inagaki, Nobuya
    Taniguchi, Atsushi
    Sakamoto, Masashi
    Koiwai, Kazuki
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A297 - A298
  • [10] Assessment of PF-06291874 (PF), a Glucagon Receptor Antagonist Administered as Monotherapy for Four Weeks in Patients with Type 2 Diabetes Mellitus (T2DM)
    Bergman, Arthur
    Tan, Beesan
    Somayaji, Veena
    Calle, Roberto A.
    Kazierad, David J.
    DIABETES, 2016, 65 : A283 - A283
123